Retooling for Modern Management of Progressive MS: An Interactive, Case-Based Activity


Fred D. Lublin, MD, FAAN, FANA
Saunders Family Professor of Neurology
Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai, New York, NY
Fred D. Lublin, MD, FAAN, FANA

Fred D. Lublin, MD is the Saunders Family Professor of Neurology at The Icahn School of Medicine at Mount Sinai and Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at that institution.

Dr. Lublin received his medical degree in 1972 from Jefferson Medical College, Philadelphia, PA. He completed his internship in Internal Medicine from the Bronx Municipal Hospital, Albert Einstein Medical Center, and his residency at the New York Hospital, Cornell Medical Center.

As a neuroimmunologist, Dr. Lublin has a special interest in immune functions and abnormalities affecting the nervous system. He has been involved in both basic science and clinical research. He and his colleagues were among the first in the country involved with studies of Interferon beta-1b, which was approved by the Food & Drug Administration in 1993 to treat the relapsing-remitting form of Multiple Sclerosis. He is currently involved with several new clinical research protocols on promising agents for treating various aspects of MS. He was chairman of the National MS Society (USA) advisory committee on clinical trials of new drugs in Multiple Sclerosis and the National Multiple Sclerosis Society’s Research Programs Advisory Committee. He was a member of the National MS Society National Board of Directors. He is past Chair of the New York City/Southern New York Chapter of NMSS Clinical Advisory Committee. He is a member of the International Medical & Scientific Board of the Multiple Sclerosis International Federation. Dr. Lublin and his colleagues at the National MS Society have re-defined the clinical course definitions of MS, updated in 2014. He has chaired a task force on the ethics of placebo-controlled trials in MS. Dr. Lublin is a member of the international panel that periodically redefines the diagnostic criteria for MS (McDonald Criteria). Dr. Lublin is co-chair of the National Institute of Neurological Diseases and Stroke MS Common Data Element committee and a member of their steering committee. He is a member of the WHO Advisory Group for the Revision of ICD-10 Diseases of the Nervous System working group on demyelinating diseases of the central nervous system. He was a Co-Chief and founding Editor of the journal Multiple Sclerosis and Related Disorders.

Dr. Lublin has published numerous scientific articles and is a member of many professional societies and advisory boards. Dr. Lublin has served as a consultant to the National Institutes of Health and to many pharmaceutical/biotech companies in all phases of new drug development and in preparation for presentation to the FDA and their advisory panels. He was the Principal Investigator of the NIH-sponsored multicenter Combination Therapy study in Multiple Sclerosis. In June of 2019, Dr. Lublin was awarded the June Halper Lifetime Achievement Award from the Consortium of Multiple Sclerosis Centers.

Aaron Miller, MD, FAAN, FANA
Medical Director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Professor and Vice-Chair for Education, Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY
Aaron Miller, MD, FAAN, FANA

Dr. Aaron Miller graduated from Brandeis University in 1964 and received his MD degree from New York University School of Medicine in 1968. Following his residency in neurology at the Albert Einstein College of Medicine, he received additional postdoctoral training in neurovirology and immunology at the Johns Hopkins University School of Hygiene and Public Health and at the Albert Einstein College of Medicine. During this time he was the recipient of a fellowship from the National Multiple Sclerosis Society.

In March, 2004 Dr. Miller assumed the position of Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at the Icahn School of Medicine at Mount Sinai. For 23 years prior to that, he headed the Division of Neurology at Maimonides Medical Center in Brooklyn, New York, where he continued to serve as co-director of the Multiple Sclerosis Care Center until 2015. Dr. Miller is also a Professor of Neurology at the Icahn School of Medicine at Mount Sinai in New York.

Dr. Miller is currently Chairman of the National Medical Advisory Committee of the National MS Society, having previously served in that position from 2002-2010. He is a past president of the Consortium of MS Centers and was the first president of the Section on Multiple Sclerosis of the American Academy of Neurology. He has participated in numerous clinical trials of new treatments for MS. He has authored two books: Multiple Sclerosis in Clinical Practice, with colleagues Dr. Fred Lublin and Dr. Patricia Coyle, and Neuroimmunology as part of the What Do I Do Now? series with Dr. Tracy DeAngelis, and edited Handbook of Relapsing-Remitting Multiple Sclerosis. He has also published more than 95 articles in peer-reviewed journals, as well as many chapters on MS and other subjects in neurology.

Dr. Miller is also very active with the American Academy of Neurology (AAN). He served as a member of the Board of Directors from 2009 through 2017 and was secretary of the Board from 2013-2017. He completed 10 years as editor of Continuum, the bimonthly continuing education publication of the AAN, in 2012, and currently serves as editor of Continuum Audio.

Dr. Miller has been cited numerous times by New York magazine in its list of top doctors and has been continually included in Castle Connolly’s America’s Top Doctors from 2009-2018.

Claire Hopkins, MA, FRCS, DM
Consultant ENT Surgeon Guy's Hospital
Professor of Rhinology King's College London, UK
Claire Hopkins, MA, FRCS, DM

Claire Hopkins, MA, FRCS, DM is a Consultant Rhinologist at Guy’s Hospital, a large tertiary referral center in London, UK, with a clinical practice covering the breadth of rhinology including sinusitis, anterior skull base work, and facial plastics. She is a Professor at King’s College London. She is the Past-President of the British Rhinological Society, Academic Chair of ENTUK/BACO and the President elect of the Royal Society of Medicine’s Section of Laryngology and Rhinology. Dr. Hopkins is co-author of the European Position Statement on Rhinosinusitis and Nasal Polyps and the International Consensus on Rhinosinusitis. She has a large research program covering all aspects of medical and surgical management of rhinitis and sinus disease, with a focus on improving outcomes in the management of nasal polyps.

Statement of Need

The approval of ocrelizumab for primary progressive multiple sclerosis (PPMS) was groundbreaking, and more recently the MS community bore witness to another major breakthrough in MS management when siponimod was approved for secondary progressive MS (SPMS). Additionally, new investigational agents such as MD1003 (high-dose biotin) and masitinib are also being evaluated for treatment of PPMS, and clinical data for both show promise for patients with SPMS.

However, despite these advances, studies have shown that gaps in knowledge and performance exist among neurologists and their care team that pose a barrier to the integration of new and emerging therapies to treat MS in clinical practice.

This CME Outfitters Live and On Demand webcast will include an interactive, case-based panel discussion featuring expert faculty who will discuss the symptoms and clinical features of progressive MS, summarize its immunopathology and the mechanisms of action (MOAs) of new and investigational disease modifying therapies (DMTs), and evaluate the latest clinical evidence on the efficacy and safety of new and emerging therapies for SPMS and PPMS.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Recognize the symptoms and clinic features of progressive MS.
  • Summarize the immunopathology of progressive MS and the MOAs of new and investigational DMTs.
  • Evaluate the latest clinic evidence of new and emerging therapies for SPMS and PPMS and engage patients in the shared decision-making process.
  • Integrate strategies for SDM to deliver patient-centered care.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Recognize the symptoms and clinical features of progressive MS.
  • Summarize the immunopathology of progressive MS and the MOAs of new and investigational DMTs.
  • Summarize the latest clinical evidence on efficacy and safety of new and emerging therapies for SPMS and PPMS.

Financial Support

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Target Audience

Neurologists, MS specialists, PAs, NPs, nurses, and pharmacists

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit  from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
Activity UAN: 0376-0000-21-062-H02-P


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Lublin reports that he receives research support from Actelion Pharmaceuticals; Biogen; Brainstorm Cell Therapeutics Inc; National Institutes of Health (NIH); National Multiple Sclerosis Society (NMSS); Novartis; and Sanofi. He has consulting agreements, serves on advisory boards, or Data and Safety Monitoring Board for Acorda Therapeutics; Actelion Pharmaceuticals/Janssen Pharmaceuticals, Inc.; Apitope; Brainstorm Cell Therapeutics Inc.; Atara Biotherapeutics, Inc.;Avotres; Biogen; EMD Serono, Inc; GW Pharmaceuticals; Immunic, Inc.; Innate Immunotherapeutics; Jazz Pharmaceuticals, Inc.; Mapi Pharma; MedDay Pharmaceuticals; MedImmune/ Viela Bio; Mylan; Novartis; Orion Biotechnology; Polpharma; Receptos, Inc./Celgene Corporation; Roche/Genentech, Inc.; Sanofi/Genzyme Corporation; Teva Pharmaceuticals; The Population Council, Inc. and TG Therapeutics. He is a speaker for Sanofi (non-promotional).

Dr. Miller reports he receives research support from F. Hoffmann-La Roche Ltd/Genentech, Inc.; Mallinckrodt; MedDay Pharmaceuticals; Novartis Pharmaceuticals Corporation; and Sanofi/Genzyme Corporation. He serves as a consultant for AbbVie: Inc.: Accordant Health Services (Caremark); Adamas Pharmaceuticals, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company/Celgene Corporation; Corrona; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Mallinckrodt; Mapi-Pharma; and Novartis Pharmaceuticals Corporation. He serves on the speakers’ bureau for Alexion Pharmaceuticals, Inc. (unbranded disease awareness programs only); Biogen Idec Inc. (unbranded disease awareness programs only); EMD Serono, Inc. (unbranded journal club); and Genentech, Inc. (unbranded disease awareness programs only).

Dr. Riley reports she receives research support from Biogen Idec Inc. She is a consultant for EMD Serono, Inc.; Genentech, Inc.: Novartis; and TG Therapeutics.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

  • Alaeddin Abukabda, MS, DMD, PhD (planning committee)
  • Evan Luberger (planning committee)
  • Jan Perez (planning committee)
  • Sharon Tordoff (planning committee)


Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.


NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-062-H02-P.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


Retooling for Modern Management of Progressive MS: An Interactive, Case-Based Activity
Event Date: 06/11/2020